Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · GHRP-6Mixed
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.
This trial studied GHRP-6 in combination with epidermal growth factor, so its effects cannot be isolated to the peptide alone. The study missed its primary endpoint, with benefit seen only in a small severe-stroke subgroup and an open-label design that limits confidence. A genuine but preliminary signal warranting further study.
Journal of clinical neurosciencen=—HumanJul 16, 2026 - Study · GHRP-6Weak / none
EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.
A preclinical mouse study testing co-administration of epidermal growth factor (EGF) with growth-hormone-releasing peptide-6 (GHRP-6) in two models of cognitive decline, aging and streptozotocin-induced impairment. In C57BL/6 mice (14–15 per group), the EGF+GHRP-6 combination was associated with improved gait (longer step length in aged animals) and better performance on memory tasks (Y-maze alternation, novel-object recognition), plus favorable shifts in genes tied to antioxidant defense, synaptic plasticity and oligodendrocyte differentiation, and reduced Nfkb1. These are preclinical findings; human data are needed before clinical conclusions can be drawn. Two further caveats: GHRP-6 was given combined with EGF, so its individual contribution cannot be isolated, and rodent cognition models translate imperfectly to human disease. For a tracked peptide, this is a mechanistic signal for GHRP-6 in a neuroprotection context, hypothesis-generating, not evidence of benefit in people.
Neurotoxicity researchn=—AnimalJul 4, 2026 - Study · GHRP-6Weak / none
A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.
This is a preclinical proteomics study in a rat stroke model examining the molecular mechanisms of combined epidermal growth factor (EGF) plus GHRP-6 co-administration in the ischemic penumbra. Researchers reported that at 3 and 24 hours after treatment, EGF+GHRP-6 was associated with modulation of 40 and 223 proteins respectively, with consistent effects on neurotransmitter-transport proteins and, at 24 hours, on antioxidant, anti-apoptotic, and hypoxia-response pathways. GHRP-6 is studied here in combination with EGF, not alone, so its independent contribution cannot be isolated. These are preclinical, mechanistic findings in rodents; human data are needed before clinical conclusions can be drawn. They add a molecular rationale to earlier reports of this combination's neuroprotective signals, but sit far upstream of clinical evidence for GHRP-6.
Pharmacological reports : PRn=—AnimalJun 8, 2026